Clinical Trials - December 16, 2025
Affibody accelerates Phase 1 study
The Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer to its second part, where higher radioactivity levels will be evaluated.
Clinical Trials - December 11, 2025
Muna Therapeutics doses first subjects in Phase 1 trial
It is a phase 1 single-ascending dose/multiple-ascending dose study of lead asset MNA-001 in healthy adult participants.
Clinical Trials - December 10, 2025
AnaCardio reports new Phase 2a results
AnaCardio has announced topline results from the Phase 2a portion of its GOAL-HF1 clinical study program evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF).
Clinical Trials - December 8, 2025
Aurealis Therapeutics announces positive Phase 2 results
The company has announced positive blinded evaluator efficacy results and completion of the Database Lock (DBL) in its DIAMEND Phase 2 clinical trial of AUP-16, the company’s lead asset for the treatment of non-healing neuro-ischemic Diabetic Foot Ulcers (DFUs).
Clinical Trials - November 26, 2025
First subject dosed in One-carbon Therapeutics study
The first subject has been dosed in the company's ODIN Phase 1/2 clinical trial evaluating TH9619, a first-in-class MTHFD1/2 inhibitor.
Clinical Trials - November 21, 2025
Evaxion announces positive data for lead antigens in CMV vaccine program
Evaxion is advancing its novel multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program.
